FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978746586> ?p ?o ?g. }

• W2978746586 endingPage "v627" @default.
• W2978746586 startingPage "v627" @default.
• W2978746586 abstract "Abstract Background Afatinib and osimertinib both inhibit sensitizing EGFR mutations (deletion 19 and L858R). In addition, osimertinib is highly active against the most frequent resistance mutation (∼60%) T790M and was originally registered for these patients (pts.). Some evidence suggests that a sequential treatment approach using 1st or 2nd gen EGFR-TKIs like afatinib in first-line, followed by a 3rd gen EGFR-TKI in T790M positive pts. may lead to overall survival rates up to 80% after 4 years. Here, we report first results of prospectively collected data within the German NIS GIDEON on pts. treated with 1st line afatinib followed by osimertinib. Methods 151 EGFR-mutated NSCLC pts. were treated with afatinib according to label until progression, death or treatment discontinuation. Data on effectiveness (ORR, DCR, PFS and 24 months OS rate) were prospectively assessed for pts. who have been treated with osimertinib following afatinib. Results A total of 30/151 (20%) pts. were treated with 1st line afatinib followed by osimertinib. 22 (73%), 7 (23%) and 1 (3%) of these pts. were initially positive for Del19, L858R and G719C, respectively. The mPFS from start of afatinib to PD under osimertinib at the time of analysis was 32.2 mo, 29.8 mo and NR (95% CI 16.4 mo - NR) for the total population, pts. with Del19 and pts. with L858R, respectively. The 24-mo-OS rate was 89.3% for all 30 pts receiving osimertinib in a later line, and 90% and 85.7% for patients with initial Del19 and L858R, respectively. Conclusions These data support the evidence that pts. with acquired T790M under afatinib may benefit from sequential TKI treatment. The frequency of T790M was higher in pts. initially tested positive for Del19, which is in line with recently published data. This analysis is limited by the small patient number, explainable by the restricted availability of osimertinib during the study conduct (March 2014 – Dec 2017). Clinical trial identification NCT02047903. Legal entity responsible for the study Boehringer Ingelheim. Funding Boehringer Ingelheim. Disclosure W. Bruckl: Advisory / Consultancy: AbbVie; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: BMS; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Celgene; Advisory / Consultancy: Chugai; Advisory / Consultancy: Lilly; Advisory / Consultancy: MSD; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: Stratifyer. M. Reck: Honoraria (self), Advisory / Consultancy: Abbot; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Merck. J. Rawluk: Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: BMS. R.M. Huber: Speaker Bureau / Expert testimony: ARIAD; Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy: Celgene; Advisory / Consultancy: Lilly; Advisory / Consultancy: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy: Clovis Oncology; Research grant / Funding (institution): Pierre Fabre; Speaker Bureau / Expert testimony: Pfizer. C. Hoffmann: Full / Part-time employment: Boehringer Ingelheim. A. Schueler: Full / Part-time employment: Boehringer Ingelheim. All other authors have declared no conflicts of interest." @default.
• W2978746586 created "2019-10-10" @default.
• W2978746586 creator A5003670561 @default.
• W2978746586 creator A5011965893 @default.
• W2978746586 creator A5021014213 @default.
• W2978746586 creator A5021369233 @default.
• W2978746586 creator A5041585764 @default.
• W2978746586 creator A5060572768 @default.
• W2978746586 creator A5084192217 @default.
• W2978746586 creator A5084767281 @default.
• W2978746586 date "2019-10-01" @default.
• W2978746586 modified "2023-09-27" @default.
• W2978746586 title "Sequential treatment with afatinib followed by 3rd generation EGFR-TKI – subgroup analysis of the GIDEON trial: A prospective non-interventional study (NIS) in EGFR mutated NSCLC patients in Germany" @default.
• W2978746586 doi "https://doi.org/10.1093/annonc/mdz260.049" @default.
• W2978746586 hasPublicationYear "2019" @default.
• W2978746586 type Work @default.
• W2978746586 sameAs 2978746586 @default.
• W2978746586 citedByCount "0" @default.
• W2978746586 crossrefType "journal-article" @default.
• W2978746586 hasAuthorship W2978746586A5003670561 @default.
• W2978746586 hasAuthorship W2978746586A5011965893 @default.
• W2978746586 hasAuthorship W2978746586A5021014213 @default.
• W2978746586 hasAuthorship W2978746586A5021369233 @default.
• W2978746586 hasAuthorship W2978746586A5041585764 @default.
• W2978746586 hasAuthorship W2978746586A5060572768 @default.
• W2978746586 hasAuthorship W2978746586A5084192217 @default.
• W2978746586 hasAuthorship W2978746586A5084767281 @default.
• W2978746586 hasBestOaLocation W29787465861 @default.
• W2978746586 hasConcept C121608353 @default.
• W2978746586 hasConcept C126322002 @default.
• W2978746586 hasConcept C143998085 @default.
• W2978746586 hasConcept C187960798 @default.
• W2978746586 hasConcept C2778087573 @default.
• W2978746586 hasConcept C2779438470 @default.
• W2978746586 hasConcept C2780586478 @default.
• W2978746586 hasConcept C71924100 @default.
• W2978746586 hasConcept C95190672 @default.
• W2978746586 hasConceptScore W2978746586C121608353 @default.
• W2978746586 hasConceptScore W2978746586C126322002 @default.
• W2978746586 hasConceptScore W2978746586C143998085 @default.
• W2978746586 hasConceptScore W2978746586C187960798 @default.
• W2978746586 hasConceptScore W2978746586C2778087573 @default.
• W2978746586 hasConceptScore W2978746586C2779438470 @default.
• W2978746586 hasConceptScore W2978746586C2780586478 @default.
• W2978746586 hasConceptScore W2978746586C71924100 @default.
• W2978746586 hasConceptScore W2978746586C95190672 @default.
• W2978746586 hasLocation W29787465861 @default.
• W2978746586 hasOpenAccess W2978746586 @default.
• W2978746586 hasPrimaryLocation W29787465861 @default.
• W2978746586 hasRelatedWork W2137046878 @default.
• W2978746586 hasRelatedWork W2518851971 @default.
• W2978746586 hasRelatedWork W2748101304 @default.
• W2978746586 hasRelatedWork W2767998373 @default.
• W2978746586 hasRelatedWork W2792513092 @default.
• W2978746586 hasRelatedWork W2899301796 @default.
• W2978746586 hasRelatedWork W2906574801 @default.
• W2978746586 hasRelatedWork W2999358396 @default.
• W2978746586 hasRelatedWork W3185413675 @default.
• W2978746586 hasRelatedWork W4382399821 @default.
• W2978746586 hasVolume "30" @default.
• W2978746586 isParatext "false" @default.
• W2978746586 isRetracted "false" @default.
• W2978746586 magId "2978746586" @default.
• W2978746586 workType "article" @default.